(Press-News.org) Contact information: Julia Capaldi
julia.capaldi@lawsonresearch.com
519-685-8500
The JAMA Network Journals
Use of calcium-channel blocker and antibiotic associated with small increased risk of kidney injury
Among older adults taking a calcium-channel blocker, simultaneous use of the antibiotic clarithromycin, compared with azithromycin, was associated with a small but statistically significant greater 30-day risk of hospitalization with acute kidney injury, according to a study published by JAMA. The study is being published early online to coincide with its presentation at the American Society of Nephrology's Kidney Week 2013.
The commonly used antibiotics clarithromycin and erythromycin are clinically important inhibitors of the enzyme CYP3A4, while azithromycin is much less so. Calcium-channel blockers are metabolized by this enzyme. Blood concentrations of these drugs may rise to harmful levels when CYP3A4 activity is inhibited. "Currently, the U.S. Food and Drug Administration warns that 'serious adverse reactions have been reported in patients taking clarithromycin concomitantly with CYP3A4 substrates, which includes hypotension [abnormally low blood pressure] with calcium-channel blockers [that are] metabolized by CYP3A4.' Yet, calcium-channel blockers and clarithromycin continue to be frequently coprescribed in routine care," according to background information in the article. When hypotension occurs, the kidney is particularly prone to injury from poor circulation. "Despite this knowledge, the risk of acute kidney injury following coprescription of clarithromycin with a calcium-channel blocker is unknown."
Sonja Gandhi, B.Sc., of Western University, London, Canada, and colleagues conducted a study to investigate the interaction between calcium-channel blockers (amlodipine, felodipine, nifedipine, diltiazem, or verapamil) and the antibiotic clarithromycin (n = 96,226), compared with azithromycin (n = 94,083), with a focus on acute kidney injury, among older adults (average age, 76 years).
Amlodipine was the most commonly prescribed calcium-channel blocker (more than 50 percent of patients).
The researchers found that coprescribing clarithromycin with a calcium-channel blocker was associated with a higher risk of hospitalization with acute kidney injury compared with coprescribing azithromycin (0.44 percent vs. 0.22 percent); in absolute terms, coprescription with clarithromycin resulted in a 0.22 percent higher incidence of hospitalization with acute kidney injury.
When examined by type of calcium-channel blocker, the risk of hospitalization with acute kidney injury was highest among patients coprescribed clarithromycin with nifedipine (absolute risk increase, 0.63 percent). Coprescription of a calcium-channel blocker with clarithromycin was also associated with a higher risk of hospitalization with hypotension (0.12 percent vs. 0.07 percent patients taking azithromycin; absolute risk increase, 0.04 percent) and all-cause mortality (1.02 percent vs. 0.59 percent patients taking azithromycin; absolute risk increase, 0.43 percent).
"Although the absolute increases in the risks were small, these outcomes have important clinical implications. Our results suggest that potentially hundreds of hospitalizations and deaths in our region may have been associated with this largely preventable drug-drug interaction. This burden on the health care system, given the high costs of managing acute kidney injury, might have been avoided," the authors write.
"… our study highlights the need for quality improvement initiatives that will mitigate the clinical effects of such drug interactions. Potential strategies may include temporary cessation of the calcium-channel blocker for the duration of clarithromycin therapy or selection of a non-CYP3A4 inhibiting antibiotic (such as azithromycin) when clinically appropriate."
###
(doi:10.l001/jama.2013.282426; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Use of calcium-channel blocker and antibiotic associated with small increased risk of kidney injury
2013-11-09
ELSE PRESS RELEASES FROM THIS DATE:
Gene hastens kidney disease progression in African-Americans
2013-11-09
Gene hastens kidney disease progression in African-Americans
A gene variant common in African-Americans predicts that people with that gene who also have chronic kidney disease (CKD) are twice as likely to progress ...
Repurposed drug may be first targeted treatment for serious kidney disease
2013-11-09
Repurposed drug may be first targeted treatment for serious kidney disease
Treatment with rheumatoid arthritis drug saved transplanted kidney in four patients, achieved remission in a fifth
A drug approved for the treatment of rheumatoid arthritis may ...
Universals of conversation
2013-11-09
Universals of conversation
Max Planck researchers found that words that signal problems with understanding are similar across languages
A word like 'Huh?' —used when one has not caught what someone just said—appears to be universal: it is found to have very ...
High-energy physicists predict new family of four-quark objects
2013-11-09
High-energy physicists predict new family of four-quark objects
New charged charmonium-like states observed at BESIII
An international team of high-energy physicists says the discovery of an electrically charged subatomic particle called Zc(4020) is ...
NASA's TRMM satellite sees Super-typhoon Haiyan strike Philippines
2013-11-09
NASA's TRMM satellite sees Super-typhoon Haiyan strike Philippines
VIDEO:
NASA's TRMM satellite data on Nov. 8 at 00:19 UTC showed Haiyan had a well-defined eye surrounded ...
Snap to attention: Polymers that react and move to light
2013-11-09
Snap to attention: Polymers that react and move to light
PITTSBURGH—Microvehicles and other devices that can change shape or move with no power source other than a beam of light may be possible through research led by the University of Pittsburgh. The researchers are ...
New therapeutic target identified for ALS and frontotemporal degeneration
2013-11-09
New therapeutic target identified for ALS and frontotemporal degeneration
A team of scientists led by researchers from the University of California, San Diego School of Medicine and Ludwig Institute for Cancer Research have identified a novel therapeutic approach ...
Montana State team overcomes challenges, proves that microbes swim to hydrogen gas
2013-11-09
Montana State team overcomes challenges, proves that microbes swim to hydrogen gas
BOZEMAN, Mont. – Scientists have long believed that microorganisms that produce methane swim toward the hydrogen gas they need to stay alive, but it has been too hard to prove in ...
Sun unleashes another X-class flare
2013-11-09
Sun unleashes another X-class flare
The sun emitted its sixth significant flare since Oct. 23, 2013, peaking at 11:26 p.m. EST on Nov. 7, 2013. Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's ...
Hubble catches stellar explosions in NGC 6984
2013-11-09
Hubble catches stellar explosions in NGC 6984
Supernovae are intensely bright objects. They are formed when a star reaches the end of its life with a dramatic explosion, expelling most of its material out into space.
The subject of this new Hubble ...